Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection

HIV/AIDS - Research and Palliative Care

Volumn 2, Issue , 2010, Pages 89-101

  Vazquez, Jose A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antifungal agents; Esophageal candidiasis; HAART; HIV; Oropharyngeal candidiasis

Indexed keywords

EID: 77954558816     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/hiv.s6660     Document Type: Review

References (108)

1. Vazquez JA, Sobel JD.Candidiasis. In: Dismukes WE, Pappas PG, Sobel JD, editors. Clinical Mycology. Oxford: Oxford University Press; 2003:143-187.
2. Kleinegger CL, Lockhart SR, Vargas K, Soll DR. Frequency, intensity, species, and strains of oral Candida vary as a function of host age. J Clin Microbiol. 1996;34:2246-2254.
3. Johnston RD, Chick EW, Johnston NS, Jarvis MA. Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditions. South Med J. 1967;60:1244-1247.
4. Stenderup A, Pedusen GT. Yeast of human origin. Acta Pathol Microbiol Scand. 1962;54:462-472.
5. Mackenzie DWR. Yeast from human sources. Sabouraudia. 1962;1:8-15.s
6. van't Wout JW. Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis. 1996;15:238-242.
7. Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993;9:455-456.
8. Cunha Villar C, Dongari-Bagtzoglou A. Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis. Expert Rev Mol Med. 2008;10(e29):1-18.
9. Chandler FW. Pathology of the mycoses in patients with the acquired immune deficiency syndrome (AIDS). Curr Topics Med Mycol. 1985;1:1-23.
10. Melbye M, Schonheyder H, Kesters L, et al. Carriage of oral Candida albicans associated with a high number of circulating suppressor T lymphocytes. [Letter] J Infect Dis. 1985;152:1356-1357.
11. 2 enhances and gamma interferon inhibits germ tube formation in Candida albicans. Infect Immunity. 1990;58:260-262.
12. Fidel PL, Lilly E, Rufener JB, et al. Longitudinal analysis of local immune function in HIV(+) subjects with oropharyngeal candidiasis. In: Program and Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 2009 September 12-15, Abstract# M-365.
13. de Repentigny L, Lewandowski D, Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Reviews. 2004;17:729-759.
14. Silverman S Jr, Gallo JW, McKnight ML, Mayer P, deSanz S, Tan MM. Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:402-407.
15. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS. 1991;5:519-525.
16. Powderly WG, Robinson K, Keath EJ. Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS. 1992;6:81-84.
17. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis. 1998;26:259-274.
18. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS. 1987;1:175-182.
19. Clotet B, Grifol M, Parro B, et al. Asymptomatic esophageal candidiasis in acquired-immunodeficiency-syndrome-related complex. [Letter] Ann Intern Med. 1986;105:145
20. Kodsi BE, Wickremesinghe PC, Kozinn PJ, Iswara K, Goldberg PK. Candida esophagitis: a prospective study of 27 cases. Gastroenterology. 1976;71:715-719.
21. Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut. 1982;23:137-139.
22. Centers for Disease Control, National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR. 2009 March 28; Vol 58.
23. Glatt AE, Chirgwin K, Landesman SH. Treatment of infections associated with human immunodeficiency virus. N Engl J Med. 1988;318:1439-1448.
24. Vazquez JA. Diagnosing and managing oropharyngeal candidiasis. Infect in Med. 2007;24:427-436.
25. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database of Syst Rev. 2006: Issue 1.
26. Kozinn PJ, Taschdjian CL, Dragutsky D, et al. Therapy of oral thrush: a comparative evaluation of gentian violet, mycostatin and amphotericin B. Monogr Ther. 1957;2:16-24.
27. Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis. 1997;24:1204-1207.
28. Quintiliani R, Owens NJ, Quercia RA, Klimek JJ, Nightingale CH. Treatment and prevention of oropharyngeal candidiasis. Am J Med. 1994;77 Suppl 4D:44-48.
29. Shectman LB, Funaro L, Robin T, Bottone EJ, Cuttner J. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med. 1984;76:91-94.
30. Pons V, Greenspan D, Debruin M, et al. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr. 1993;6:1311-1316.
31. Cardot JM, Chaumont C, Dubray C, Costantini D, Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. Br J Clin Pharmacol. 2004;58:345-351.
32. Vazquez JA, Epstein J, Attali P. A multicenter, randomized trial evaluating the efficacy and safety of miconazole mucoadhesive buccal tablets (MMBT) versus clotrimazole troches (CT) for the treatment of oropharyngeal candidiasis (OPC) in subjects with HIV/AIDS:SMiLES Trial. In: Program and Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009 September 12-15, Abstract# M-1245.
33. Attali P, Vazquez J, Bensadoun RJ, Dupont B. Evaluation of miconazole mucoadhesive buccal tablet: a novel, once daily, antifungal regimen for the treatment of oropharyngeal candidiasis. 44th American Society of Health System Pharmacist Mid-Year Clinical Meeting and exhibition, The Venetian Hotel, Las Vegas, NV, 2009 Dec 6-10, Abstract 6-068.
34. Bensadoun RJ, Daoud J, El Gueddari R, et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis. Cancer. 2008;112:204-211.
35. Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: a controlled study. J Infect Dis. 1983;147:1060-1063.
36. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Eng J Med. 1994;330:263-272.
37. DeWit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1989;1:746-748.
38. Meyer JM, Rodvold KA. Drug biotransformation by the cytochrome P-450 enzyme system. Infect Med. 1996;6:452-464.
39. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:685-693.
40. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 1990;12 Suppl 3:S334-S337.
41. Meunier F, Aoun M, Gerard M. Therapy of oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs ketoconazole. Rev Infect Dis. 1990;12 Suppl 3: S364-S368.
42. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1990;34:2267-2268.
43. Kowalsky SF, Dixon DM. Fluconazole: a new antifungal agent. Clin Pharm. 1991;10:179-194.
44. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46:147-150.
45. Tucker RM, Denning DW, Hanson LH, et al. Interactions of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165-174.
46. Van de Velde VJS, Van Peer AP, Heykants JJP, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16:424-428.
47. Data on File. Janssen Pharmaceutica, Beerse, Belgium.
48. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution compared with capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42:1862-1865.
49. Graybill JR, Vazquez J, Darouiche RO, et al. Itraconazole oral solution: a novel and effective treatment for oropharyngeal candidiasis in HIV/ AIDS patients. Am J Med. 1998;104:33-39.
50. Herbrecht R. Posaconazole: a potent extended spectrum triazole antifungal for the treatment of serious fungal infections. Int J Clin Practice. 2004;58:612-624.
51. Vazquez JA. Posaconazole for the management of mucosal candidiasis. Future Microbiol. 2007;2:245-256.
52. Vazquez JA. Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. Therap Clin Risk Management. 2007;3:533-542.
53. Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004;53:74-80.
54. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004;48: 2124-2131.
55. Courtney R, Sansone A, Calzetta A, et al. The effect of a nutritional supplement (Boost® Plus) on the oral bioavailability of posaconazole. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003 Sept 14-17, Chicago, IL.
56. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57:218-222.
57. Wexler D, Laughlin M, Courtney R, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21:645-650.
58. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-1186.
59. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitroin vivo correlation in HIV-infected patients. AIDS. 1994;8:945-950.
60. Quereda C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1996;15:30-37.
61. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE.Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis. 1997;24:28-34.
62. Dronda F, Alonso-Sanz M, Laguna F, et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIVinfected patients. Eur J Clin Microbiol Infect Dis. 1996;15:446-452.
63. Chryssanthou E, Torssandeer J, Petrini B. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis. 1995;27:391-395.
64. Ginsburg CH, Braden GL, Tauber AI, Trier JS. Oral clotrimazole in the treatment of esophageal candidiasis. Am J Med. 1981;71:891-895.
65. De Wit S, Urbain D, Rahir F, Weerts D, Clumeck N. Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. Eur J Clin Microbiol Infect Dis. 1991;10:503-505.
66. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med. 1992;117:655-660.
67. Laine L, Rabeneck L. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther. 1995;9:553-556.
68. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis. 1997;176:227-232.
69. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis. 1995;27:613-617.
70. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, DiLorenzo G. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterol. 1996;111:1169-1177.
71. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12:40-79.
72. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447-1454.
73. Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy. 1996;42:308-314.
74. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo controlled study. Endoscopy. 1995;27:377-383.
75. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacother. 2007;27:369-388.
76. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus Amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2001;33:1529-1535.
77. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized, doubleblind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294-299.
78. de Wet NTE, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21:899-907.
79. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39:770-775.
80. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis. 1995;21 Suppl 1:S99-S102.
81. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials. 2007;8:86-97.
82. Stevens DA, Greene I, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med. 1991;151:2458-2464.
83. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332:700-705.
84. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis. Clin Infect Dis. 2005;41:1473-1480.
85. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:689-696.
86. Vazquez JA, Sobel JD. Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host. Excerpta Medica. Abstract, 1997;1-11.
87. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd Edition. Approved Standard M27-A3, Clinical and Laboratory Standards Institute, Wayne, PA, 2008.
88. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993;37:2449-2453.
89. Revankar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:960-963.
90. Horn CA, Washburn RG, Givner LB, Peacock JE Jr, Pegram PS. Azoleresistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS. 1995;9:533-534.
91. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-225.
92. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med. 1991;20:332-336.
93. Parving H. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med.1997;126:332-333.
94. Philips P, Zemcov J, Mahmood W, Montaner JSG, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS. 1996;10:1369-1376.
95. Eichel M, Just-Nübling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses. 1996;39 Suppl 1: 102-106.
96. Cartledge JD, Midgley J, Gazzard BG. Itraconazole cyclodextrin solution: the role of in 6 vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS. 1997;11:163-168.
97. Coppola S, Angarano G, Montagna MT, et al. Efficacy of itraconazole in treating AIDS-associated infections due to Candida krusei. Eur J Epidemiol. 1995;11:243-244.
98. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44:607-614.
99. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1997;41:575-577.
100. Zingman BS. Treatment of mucosal candidiasis in HIV-infected patients. J Mycol Med. 1996;6:3-11.
101. Zingman B. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. [Letter] N Engl J Med. 1996;334:1674-1675.
102. Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis. 1995;171:1448-1454.
103. Swindells S, Kleinschmidt DR, Hayes FA. Pilot study of adjunctive GM-CSF (yeast-derived) for fluconazole-resistant oral candidiasis in HIV-infection. Infect Dis Clin Practice. 1997;6:278-279.
104. Vazquez JA, Gupta S, Villanueva A. Role of rhu-GM-CSF as adjunctive treatment of antifungal refractory oropharyngeal candidiasis in patients with AIDS. Eur J Clin Microbiol. 1998;17:781-783.
105. Vazquez JA, Vaishampayan J, Arganoza MT, Richards S, Boikov D, Sobel JD. Use of an over the counter product, Breathaway® (melaleuca oral solution), as an alternative agent for refractory oropharyngeal candidiasis in AIDS patients. AIDS. 1998;12:1033-1037.
106. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS. 1991;5:1367-1371.
107. Barchiesi F, Giacometti A, Arzeni D, et al. Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. J Chemother. 1992;4:381-386.
108. de Repentigny L, Ratelle J. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Chemotherapy. 1996;42:374-383.